| Name | Title | Contact Details |
|---|
Engineering next‑generation, brain‑penetrant cancer therapies.
Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health.
There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.
ZielBio is an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes. Our proprietary drug discovery platform Zielfind™ combines the power of functional, high throughput screening with large content data analytics to identify high value targets. We have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind™.
With Vytelle, cattle producers increase accuracy of feed intake and bodyweight measurement, improve certainty of genetic selection and accelerate progress.